ATHE TOP THE

4-8-03

Atty Docket No: US-CH02.02

#29

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

In re Application of:	) Date: April 5, 2003 APR 1 0 2003
Ma et al.	TECH CENTER 1600/2900
Serial No.: 09/801,115	TECH CENTER 1600/2900 ) Group Art Unit: 1647
Filed: March 7, 2001	) Examiner: Bridget E. Bunner
For: Chemokine-Like Factors (CKLFs) With Chemotactic And Hematopoietic Stimulating Activities	) ) )

## SUBMITTING AMENDED SEQUENCE LISTING PURSUANT TO 37 C.F.R. 1.821(c) AND 1.825(d)

Commissioner for Patents Washington, D.C. 22202

Sir:

Applicant resubmits the amended Sequence Listing in response to the "Notice to Comply" dated March 24, 2003, in compliance with 37 C.F.R. 1.821(c) and 1.825(d).

#### **CERTIFICATE OF MAILING BY EXPRESS MAIL**

Express Mail mailing label numberEF294818026US
I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelop addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlingtor VA22202.
on 4/5/2003
Typed or printed name of person signing this certificate
Yi Li
Signature

#### **REMARKS**

Applicants submit herein (by Express Mail) the amended Sequence Listing on paper copy and in computer readable form which was damaged in the previous submission.

Applicants respectfully submit that the content of the paper and computer readable copies are the same.

Respectfully submitted.

Registration No. 44,211

Agent for Applicant

Telephone: (786) 242-9349

Address correspondence to:

**CUSPA Technology Law Associates** 11820 SW 107 Avenue Miami, FL 33176



#### **Notice to Comply**

Application No.	Applicant(s)
09/801,115	Ma et RECEIVED
Examiner	Art Unit
Bridget E. Bunner	1647 APR 1 0 2003

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SECUENTER 1600/2900 **DISCLOSURES** 

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1,821

	s requiremente for each a disclosure as set forth in 37 C.F.K. 1.621 - 1.625 for the following reason(s):
$\boxtimes$	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
$\boxtimes$	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
$\boxtimes$	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
	plicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
⊠ into	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry the specification.
	A statement that the content of the paper and computer readable copies are the same and, where

applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

Technical Assistance.....703-287-0200 To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

1600

### **CRF** Problem Report

Revised 01/29/2002

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF): Application Serial Number: Filing Date: Date Processed by STIC: STIC Contact: Mark Spencer, 703-308-4212 FEB 1 9 2003 Nature of Problem: The CRF (was): melted TECH CENTER 1600/2900 (circle one) Damaged of Unreadable (for Unreadable, see attached) Blank (no files on CRF) (see attached) Empty file (filename present, but no bytes in file) (see attached) Virus-infected. Virus name: \_\_\_\_\_ The STIC will not process the CRF. Not saved in ASCII text Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should only be the Sequence Listing. Did not contain a Sequence Listing. (see attached sample) Other: PLEASE USE THE CHECKER VERSION 3.1 PROGRAM TO REDUCE ERRORS. **SEE BELOW FOR ADDRESS:** http://www.uspto.gov/web/offices/pac/checker Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses: 1. EFS-Bio (<a href="http://www.uspto.gov/ebc/efs/downloads/documents.htm">http://www.uspto.gov/ebc/efs/downloads/documents.htm</a>, EFS Submission User Manual, ePAVE) 2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 3. Hand Carry directly to: U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202 Or U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202 4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

TECHNOLOGY